Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30892315 | 0.90 | SYK (0.64) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL6641476 | 0.90 | SYK (0.64) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL30878977 | 0.89 | NPSR1 (0.65) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL2627347 | 0.89 | SYK (0.60) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL2386230 | 0.86 | SYK (0.59) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL2633030 | 0.85 | SYK (0.57) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL2627315 | 0.85 | SYK (0.60) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL12942870 | 0.84 | SYK (0.64) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL13495931 | 0.84 | SYK (0.59) | SYKSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL655545 | 0.84 | SYK (0.59) | SYKSMN1; SMN2NPSR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-1054004-B1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-6432963-B1 | ANTIINFLAMMATORY AGENTS; TYROSINE KINASE INHIBITOR | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1054004-A1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | SYK, BTK, LCK | SYK 1/4885SMN1; SMN2 3771/4885NPSR1 4344/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | SYK 72/4885SMN1; SMN2 3606/4885NPSR1 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.